HOW TO OPTIMALLY MANAGE PATIENTS TO ENSURE THEY RECEIVE MAXIMUM TREATMENT BENEFIT
Patient is a 65-year-old woman
07/2010: Right mastectomy + lymphadenectomy: IDC 3 cm, 1 positive node 1/10, ER 90%, PR 90%, HER2 0
AC × 4 followed by weekly paclitaxel × 12
Tamoxifen followed by letrozole (03/2011-03/2016)
11/2017: Relapse
Bone metastases and right axillary lymph node
MR:
Diffused bone metastases
Right axillary:
Lymph node of 2 cm
Bone biopsy:
IDC metastases, ER 90%, PR 10%, HER2 0
PFNA:
Carcinoma
Tumour markers:
CEA: 1.7, CA 15-3: 78
DIAGNOSIS:
Bone and lymph node metastatic breast cancer
Based on the results of MONALEESA-2 trial:
ribociclib 600mg/day 3 weeks on/1 week off
+
letrozole 2.5mg/day continuous dosing
The patient is on the same schedule.
She remains in response.
FEMALE, 65-YEAR-OLD
| Patient presentation and diagnosis 2010 |
November |
March 2018 |
| DIAGNOSIS: Right IDC 3 cm, 1 positive node 1/10, ER 90%, PR 90%, HER2- |
Relapse: bone metastases and right axillary lymph node |
Bone and axillary lymph node response Neutropenia G2, arthralgia G1, fatigue G1 |
| TREATMENT: Right mastectomy + lymphadenectomy Chemotherapy Tamoxifen followed by letrozole |
TREATMENT: ribociclib 600mg for 21 days + letrozole 2.5mg once daily |
Treatment ongoingTreatment ongoing |
Rapid and powerful efficacy
Convenience for an optimised treatment experience
Safety profile well characterised
Predictable: AEs typically appeared early and resolved with appropriate management
Manageable
- AEs were managed through dose modifications
- Kisqali. SUMMARY OF PRODUCT CHARACTERISTICS. August 2017
- Hortobagyi GN et al. Updated results from MONALEESA-2, a phase III trial of first-line Kisqali plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology 29: 1541–1547, 2018
Autonomous University of Barcelona, Department of Medicine, Barcelona, Spain
This case was created by Mireia Margeli, MD
Author takes full responsibility for presented information which reflect author’s stand/practice and might not be in line with local approved SmPC.